Stifel Remains Sidelined on Alexion Pharma (ALXN) Following FDA Approval of Ultomiris
Tweet Send to a Friend
Stifel analyst, Paul Matteis, reiterated a Hold rating and $136.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following earlier than ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
